Table 3.
Summary statistics for mortality counts, population characteristics and service characteristics
| Summary statistics in this study median (IQR) | |
|---|---|
| Mortality data | |
| Indirectly standardised CHD mortality | 95.9 (78.3, 119.9) |
| Indirectly standardised CHD mortality—under 75 | 92.4 (64.0, 135.6) |
| Crude rate per 1000 | 1.30 (0.95, 1.57) |
| Crude rate per 1000—under 75 | 0.43 (0.28, 0.58) |
| Practice characteristics | |
| Deprivation indices | 16.2 (10.0, 27.0) |
| Percentage of GP list on diabetes register | 3.8 (3.3, 4.4) |
| Percentage of White ethnicity | 89.9 (77.5, 94.1) |
| Percentage of population who are over 65 | 14.7 (12.1, 17.0) |
| Percentage of population who are male | 50.2 (49.5, 51.2) |
| List size | 6435 (3749, 10319) |
| Service characteristics | |
| GPs/1000 | 0.55 (0.47, 0.64) |
| Percentage of patients with recalled perception of being able to see preferred GP | 88 (80, 93) |
| Percentage of GP registered list on hypertension register | 12.3 (11.0, 14.7) |
| The percentage of patients with any or any combination of the following conditions: coronary heart disease, stroke or TIA, hypertension, diabetes, COPD or asthma who smoke and whose notes contain a record that smoking cessation advice or referral to a specialist service, where available, has been offered within the previous 15 months SM02 | 94 (92, 96) |
| The percentage of patients with CHD whose last measured total cholesterol level (measured in the previous 15 months) is ≤5 mmol/L CHD08 | 82 (78, 87) |
| The percentage of patients with CHD with a record in the previous 15 months that aspirin, an alternative antiplatelet therapy, or an anticoagulant is being taken (unless a contraindication or adverse effects are recorded) CHD09 | 95 (93, 97) |
| CHD overall achievement score10 | 83 (80, 86) |
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; GP, general practitioner; TIA, transient ischaemic attack.